Koss Olinger Consulting LLC Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Koss Olinger Consulting LLC made a new investment of $978,000 in IQVIA Holdings Inc., acquiring 5,545 shares during the first quarter.
• Several hedge funds significantly increased their stakes in IQVIA, with Citigroup Inc. raising its holdings by 236.3%.
• Analysts project a Moderate Buy consensus rating for IQVIA, with an average price target of $228.62.

Koss Olinger Consulting LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 5,545 shares of the medical research company's stock, valued at approximately $978,000.

Several other hedge funds and other institutional investors have also made changes to their positions in IQV. Pacer Advisors Inc. raised its position in shares of IQVIA by 5,036.1% during the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock valued at $153,681,000 after buying an additional 854,732 shares in the last quarter. Canada Pension Plan Investment Board raised its position in shares of IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after buying an additional 712,958 shares in the last quarter. D. E. Shaw & Co. Inc. raised its position in shares of IQVIA by 211.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company's stock valued at $189,691,000 after buying an additional 655,153 shares in the last quarter. Marshall Wace LLP raised its position in shares of IQVIA by 85.4% during the 4th quarter. Marshall Wace LLP now owns 954,294 shares of the medical research company's stock valued at $187,528,000 after buying an additional 439,649 shares in the last quarter. Finally, Cadian Capital Management LP purchased a new stake in shares of IQVIA during the 4th quarter valued at about $78,604,000. Institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

IQV has been the topic of a number of recent analyst reports. Cowen reissued a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Robert W. Baird increased their price objective on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Evercore ISI increased their price objective on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and reduced their target price for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. Finally, Mizuho raised their target price on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Seven investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.

IQVIA Stock Up 3.3%

NYSE IQV traded up $6.03 on Tuesday, hitting $186.12. The stock had a trading volume of 1,487,624 shares, compared to its average volume of 2,004,990. The business's fifty day moving average price is $167.06 and its 200 day moving average price is $168.77. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88. The stock has a market cap of $31.64 billion, a price-to-earnings ratio of 26.93, a price-to-earnings-growth ratio of 1.97 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the previous year, the company earned $2.64 earnings per share. The business's revenue for the quarter was up 5.3% on a year-over-year basis. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.